
Retatrutide
CAS No. 2381089-83-2
Retatrutide( —— )
Catalog No. M36652 CAS No. 2381089-83-2
Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 375 | Get Quote |
![]() ![]() |
5MG | 591 | Get Quote |
![]() ![]() |
10MG | 947 | Get Quote |
![]() ![]() |
25MG | 1352 | Get Quote |
![]() ![]() |
50MG | 1831 | Get Quote |
![]() ![]() |
100MG | 2421 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRetatrutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionRetatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
-
DescriptionRetatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
-
In Vitro——
-
In VivoAnimal Model:Diet-induced obese (DIO) male C57/Bl6 mice (24-25 weeks, 40-51 g) Dosage:10 mL/kg Administration:Subcutaneous (SC) injection, cycle every 3 days, for 21 days Result:Decreased body weight and improved glycemic control.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2381089-83-2
-
Formula Weight4731.33
-
Molecular FormulaC221H342N46O68
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (10.57 mM; Ultrasonic ) H2O : 33.33 mg/mL (7.04 mM; ultrasonic and adjust pH to 7 with NaOH)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.?
molnova catalog



related products
-
LGD-6972
LGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist.
-
HAEGTFTSD
HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
-
GCGR-IN-17
A highly potent glucagon receptor antagonist with Ki of 14 nM for hGCGR.